Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Paul Glezen

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Vaccine|July 10, 2003
Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodiesPedro A Piedra, Alan M Jewell, Stanley G Cron, et al.
The Pediatric Infectious Disease Journal|April 11, 2008
Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trialManjusha J Gaglani, Pedro A Piedra, Mark Riggs, et al.
The Journal of Infectious Diseases|March 28, 2003
Immunogenic protein contaminants in pneumococcal vaccinesJigui Yu, David E Briles, Janet A Englund, et al.
Vaccine|July 12, 2005
A personnel time-motion study of intranasal influenza vaccination in healthy childrenMichael L Washington, Sharon G Humiston, Peter B Fauerbach, et al.
Journal of Clinical Microbiology|November 26, 2011
Picornavirus, the most common respiratory virus causing infection among patients of all ages hospitalized with acute respiratory illnessRobert L Atmar, Pedro A Piedra, Shital M Patel, et al.
The Journal of Infection|April 23, 2005
Respiratory viral infections in patients with chronic, obstructive pulmonary diseaseJ David Beckham, Ana Cadena, Jiejian Lin, et al.
American Journal of Epidemiology|August 14, 2003
Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance culturesM Elizabeth Halloran, Ira M Longini, Manjusha J Gaglani, et al.
American Journal of Obstetrics and Gynecology|April 23, 2005
Safety of influenza vaccination during pregnancyFlor M Munoz, Anthony J Greisinger, Oscar A Wehmanen, et al.
Pediatrics|August 19, 2007
Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in childrenPedro A Piedra, Manjusha J Gaglani, Claudia A Kozinetz, et al.
Pediatrics|September 6, 2005
Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trialPedro A Piedra, Manjusha J Gaglani, Mark Riggs, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Vaccine|July 10, 2003
Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodiesPedro A Piedra, Alan M Jewell, Stanley G Cron, et al.
The Pediatric Infectious Disease Journal|April 11, 2008
Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trialManjusha J Gaglani, Pedro A Piedra, Mark Riggs, et al.
The Journal of Infectious Diseases|March 28, 2003
Immunogenic protein contaminants in pneumococcal vaccinesJigui Yu, David E Briles, Janet A Englund, et al.
Vaccine|July 12, 2005
A personnel time-motion study of intranasal influenza vaccination in healthy childrenMichael L Washington, Sharon G Humiston, Peter B Fauerbach, et al.
Journal of Clinical Microbiology|November 26, 2011
Picornavirus, the most common respiratory virus causing infection among patients of all ages hospitalized with acute respiratory illnessRobert L Atmar, Pedro A Piedra, Shital M Patel, et al.
The Journal of Infection|April 23, 2005
Respiratory viral infections in patients with chronic, obstructive pulmonary diseaseJ David Beckham, Ana Cadena, Jiejian Lin, et al.
American Journal of Epidemiology|August 14, 2003
Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance culturesM Elizabeth Halloran, Ira M Longini, Manjusha J Gaglani, et al.
American Journal of Obstetrics and Gynecology|April 23, 2005
Safety of influenza vaccination during pregnancyFlor M Munoz, Anthony J Greisinger, Oscar A Wehmanen, et al.
Pediatrics|August 19, 2007
Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in childrenPedro A Piedra, Manjusha J Gaglani, Claudia A Kozinetz, et al.
Pediatrics|September 6, 2005
Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trialPedro A Piedra, Manjusha J Gaglani, Mark Riggs, et al.
Pageof 5